Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Central Nervous System Neoplasms 36Neuroblastoma 35Brain Neoplasms 25Medulloblastoma 22Astrocytoma 10Glioma 8Glioblastoma 7Choroid Plexus Neoplasms 7Rhabdoid Tumor 6Oligodendroglioma 6Neuroectodermal Tumors, Primitive 6Ependymoma 6Breast Neoplasms 6Sarcoma 5Ovarian Neoplasms 5Neoplasms 5Ganglioneuroblastoma 5Esthesioneuroblastoma, Olfactory 5Carcinoma, Non-Small-Cell Lung 5Testicular Neoplasms 4Testicular Germ Cell Tumor 4Small Cell Lung Carcinoma 4Lung Neoplasms 4Head and Neck Neoplasms 4Gliosarcoma 4Thyroid Neoplasms 3Teratoma 3Squamous Cell Carcinoma of Head and Neck 3Seminoma 3Endodermal Sinus Tumor 3

Interventions

Vincristine 1Radiotherapy 1Pemetrexed 1Neuropsychological Tests 1HhAntag691 1Gemcitabine 1Exercise 1Cyclophosphamide 1Craniospinal Irradiation 1Control Groups 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Infratentorial Neoplasms × Cisplatin × CNS × Clear all
NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
660 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡